Search clinical trials for: Empagliflozin 10 MG

Total 12601 results

Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
AstraZeneca

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

Spain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Saudi Arabia, Australia, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Israel, Brazil, Finland, Greece, Mexico, United Kingdom and more
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
AstraZeneca

Recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

Spain, Italy, China, Vietnam, United States, Brazil, Canada, Malaysia, Poland, Taiwan, Austria, Bulgaria, Chile, United Kingdom, Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
Collegium Medicum w Bydgoszczy

Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER)

Metabolic Syndrome

Poland
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Butler Hospital
National Institute of Mental Health (NIMH)

Completed

Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users

Substance-Related Disorders | Depression | HIV Infections

United States
Yale University
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease (EMPA-PD)

End Stage Renal Disease on Dialysis

United States
Abramson Cancer Center of the University of Pennsylvania

Terminated

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia (UPCC04407)

Acute Myeloid Leukemia

United States
Medical University of Vienna
Vienna Dialysis Center

Recruiting

SGLT2 Inhibition in Hemodialysis (DAPA-HD)

Diabetes Mellitus, Type 2 | Hemodialysis | Chronic Kidney Disease | Kidney Failure | Left Ventricular Hypertrophy

Austria
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
The University of Hong Kong
Research Grant Council

Recruiting

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B

Cirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 Inhibitors

Hong Kong
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Non-alcoholic Fatty Liver Disease

Hong Kong
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
AstraZeneca

Terminated

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Type 2 Diabetes Mellitus

Thailand, Vietnam
Anita Saraf
The Pittsburgh Foundation

Not yet recruiting

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease (EmpaCHD)

Heart Failure | Adult Congenital Heart Disease

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
China National Center for Cardiovascular Diseases

Recruiting

Use of SGLT2i in noHCM With HFpEF

Hypertrophic Cardiomyopathy | Heart Failure With Preserved Ejection Fraction

China
Central Hospital, Nancy, France

Not yet recruiting

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. (EMPASHOCK)

Cardiogenic Shock

France
Stanford University

Completed

Empagliflozin in Diuretic Refractory Ascites (DRAin-Em 01)

Liver Cirrhosis | Cirrhosis | Ascites | Ascites Hepatic | Sodium-Glucose Transporter 2 Inhibitors

United States
Zhijun Sun

Enrolling by invitation

EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction

Heart Failure | Heart Failure With Preserved Ejection Fraction

China
Ann & Robert H Lurie Children's Hospital of Chicago
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease (SGLT2I-IN-KIDS)

Chronic Kidney Diseases | Pediatric Kidney Disease

United States
Amsterdam UMC, location VUmc

Recruiting

Empagliflozin in Pulmonary Arterial Hypertension (Emphower PoC)

Idiopathic Pulmonary Arterial Hypertension

Netherlands
University of Texas Southwestern Medical Center
Boehringer Ingelheim

Completed

Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction

Diabetes Mellitus | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction

United States
Zhijun Sun

Enrolling by invitation

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Heart Failure | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction

China
Rajaie Cardiovascular Medical and Research Center
Tehran Heart Center

Recruiting

Empagliflozin to Prevent Post-Operative Atrial Fibrillation (EMPOAF)

CABG | Post-operative Atrial Fibrillation

Iran, Islamic Republic of
Washington D.C. Veterans Affairs Medical Center
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD (NDKD)

Chronic Kidney Diseases

United States
Yale University

Recruiting

Effects of Acute and Chronic Empagliflozin Heart Failure (EMPA HF)

Heart Failure

United States
Sadat City University

Recruiting

Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Ulcerative Colitis

Egypt
Juntendo University
Boehringer Ingelheim

Recruiting

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure (EMPA-AHF)

Acute Heart Failure

Japan
Jacob Moller
Rigshospitalet, Denmark; University Hospital Bispebjerg and Frederiksberg; Hillerod... and other collaborators

Recruiting

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Heart Failure | Obesity

Denmark
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
Hannover Medical School
Boehringer Ingelheim

Not yet recruiting

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) (EMPA-PKD)

Autosomal Dominant Polycystic Kidney
Chulalongkorn University

Not yet recruiting

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 (TREAT-CRS)

Empagliflozin in Cardiorenal Syndrome Type 1

Thailand
Chinese University of Hong Kong

Recruiting

Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction (EMPA)

Acute Heart Failure

Hong Kong
Chulalongkorn University

Recruiting

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Empagliflozin in Post AKI Stage 2-3

Thailand
Jacob Moller
Rigshospitalet, Denmark; University Hospital Bispebjerg and Frederiksberg; Hillerod... and other collaborators

Recruiting

The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

Heart Failure | Obesity

Denmark
Assiut University

Completed

Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients (Fatty liver)

Fatty Liver Disease

Egypt

Search clinical trials for: Empagliflozin 10 MG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations